03 Apr Rep. Aderholt Raises Premium Cigar Question in Appropriations Hearing
Earlier today, the held a hearing for the Food and Drug Administration (FDA)’s Fiscal Year 2020 budget requests. Members of the committee had the opportunity to ask FDA Commissioner Scott Gottlieb, who will be leaving the FDA at the end of the week, specific questions regarding the administration’s intentions.
Congressman Robert Aderholt (AL-4) posed his question by referring to the FDA’s proposed framework for the Substantial Equivalence process, which was announced last week. He then asked, “Given that FDA remains in the early stages of addressing this process, would it not be appropriate to delay the implementation of the regulations relative to the narrower premium cigar category until FDA has clear guidance for these small manufacturers on how to keep their products on the market?”
Gottlieb responded that in addition to the newly proposed rule, FDA has grandfathered over 1,000 cigars and already pushed back the application deadlines for cigars while they accepted comments from an advanced notice of proposed rulemaking (ANPRM). He explained that the FDA is currently still sorting through those comments and has not come to any further conclusions.
IPCPR applauds Congressman Aderholt for standing up for premium cigars and seeking clarity from the FDA. We look forward to continuing to engage with lawmakers and the FDA to seek fair treatment of premium cigars. To watch the hearing CLICK HERE. For legislative questions, please contact Tori Ellington by emailing email@example.com.